Group 1 - Johnson & Johnson (NYSE: JNJ) is being highlighted as a strong investment opportunity, particularly in the high-growth pharmaceutical sector, with a focus on cancer treatments [1] - The company is divesting from non-proprietary products, such as artificial joints, to concentrate on its core pharmaceutical business [1] - Johnson & Johnson offers a yield of over 2.7%, making it an attractive option for investors looking for stable returns [1] Group 2 - Johnson & Johnson develops and sells a wide range of healthcare products, including pharmaceuticals and medical technologies, with a focus on areas such as immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2] - The company also provides surgical systems, orthopedic solutions, cardiovascular devices, and vision care products, indicating a diverse product portfolio [2]

Core Insights - High-rolling investors are bullish on Amgen (NASDAQ:AMGN), indicating potential privileged information influencing their trading decisions [1] - The sentiment among major traders is predominantly bullish, with 75% of options trades being calls and only 0% bearish [2] - Significant price targets for Amgen have been identified, ranging from $290.0 to $400.0 over the last three months [3] Options Trading Activity - A total of 8 options trades were detected for Amgen, with a notable imbalance favoring calls over puts [1][2] - The total trade price for the identified options includes $422,130 for calls and $30,600 for a put [2] - Recent options trades include various strike prices, with significant trades such as a bullish call for $400.00 expiring on January 16, 2026, totaling $180.6K [8] Company Overview - Amgen is a leader in biotechnology, known for its therapeutics including Epogen, Neupogen, and Enbrel, among others [9] - The company has expanded its portfolio through acquisitions and recent drug launches, including treatments for cancer and rare diseases [9] - Amgen's current market position is supported by expert ratings, with an average target price of $314.67 from three analysts [11][12] Current Market Status - Amgen's stock is currently trading at $337.81, reflecting a 0.45% increase [14] - The stock's trading volume is reported at 163,220, with RSI readings suggesting it may be overbought [14] - Anticipated earnings release is scheduled in 82 days, which may impact future trading activity [14]

Market Overview - U.S. stock futures rose as traders reacted to the end of the government shutdown, with Dow Jones Industrial Average futures up 0.2%, S&P 500 futures up 0.2%, and Nasdaq 100 futures up 0.3% [1][13] - The Dow Jones Industrial Average closed above 48,000 for the first time in history, indicating a strong market rally supported by investor relief over the shutdown resolution [5][13] Economic Impact - The Congressional Budget Office estimates that the U.S. economy may lose about $11 billion by the end of 2026 due to lost work output and delayed government operations resulting from the shutdown [2] - Key economic data releases, such as the Consumer Price Index and the October jobs report, may be "permanently impaired" due to the shutdown, leading to expectations of choppy data in the coming weeks [2][12] Sector Performance - Technology sector led gains, with AI-related stocks like Nvidia experiencing strong rebounds, while notable gainers among Dow components included Merck, Amgen, Nike, Johnson & Johnson, McDonald's, Walt Disney, Honeywell, Apple, and Goldman Sachs, with increases ranging from about 2% to near 5% [4][5] - Some stocks, such as Energy Transfer LP and Philip Morris International, experienced declines [4] Corporate Earnings - Cisco Systems raised its fiscal 2026 outlook, expecting up to $61 billion in revenue, which is around $1 billion above its earlier estimate and stronger than Wall Street projections, leading to an 8% increase in shares during after-hours trading [6][7][15] - The jump in Cisco's stock is attributed to booming demand for AI infrastructure, as the company rolls out upgraded chips and networking gear to support modern AI workloads [7][15] Global Market Sentiment - European stocks showed calm strength, with the Stoxx Europe 600 edging up 0.2%, while Asian markets posted solid gains, following Wall Street's performance and the resolution of the U.S. shutdown [8][11] - Oil prices drifted lower, with Brent crude falling to $62.57 per barrel and WTI crude declining to $58.35 [9][15] - Bond yields moved slightly higher as investors shifted toward stocks, with the U.S. 10-year Treasury yield increasing to 4.087% [9][10]

Market Overview & Strategy - The market demonstrates strength with rotation into reasonably priced stocks outside the AI space, indicating a broader base beyond data center spending [2][3][4] - A rotation into undervalued companies that could catch fire is happening, defying the bears [4] - Growth investing in non-tech style is making a comeback [22][26] Travel & Leisure Sector - Travel stocks, including airline stocks like United and Delta, and Expedia, are recovering as the government shutdown ends [5] - Cruise lines and hotels are expected to experience similar gains as travel stocks [5] - Analysts are anticipated to turn positive on travel stocks, including Marriott and Wynn Resorts, as the government reopens and China's economy strengthens [6][7] Restaurant Sector - Restaurants like Brinker (parent of Chili's), Texas Roadhouse, and Chipotle are showing signs of recovery [11] - Brinker reported a terrific quarter, while Texas Roadhouse was impacted by beef inflation [11][12] - Starbucks' last quarter was positive, and Darden (Olive Garden) is a buy due to consumer confidence [13][14] Retail Sector - Retail owners are encouraged to promote usual suspects, especially with the collapse of oil prices [14] - On Holdings reported a remarkable quarter with no planned holiday discounts [15] - Retailers like Urban Outfitters, Macy's, and Costco are highlighted as potentially undervalued [16][17] Financial Sector - Bank stocks are considered absurdly cheap compared to the rest of the market [18] - A surge in IPO filings is expected from Goldman Sachs, Bank of America, JP Morgan, and Wells Fargo [19] Healthcare Sector - Amgen announced a breakthrough in Repatha, an injection to prevent heart attacks [20] - Pfizer is suggested as a potential buy to enter the lucrative weight loss business [20] Company Specific - Celsius had a bad miss in the last quarter, and it's recommended to wait another quarter [23][24] - Deere is expected to benefit from farmers receiving checks [25] - Flood Entertainment is on the move after reporting good earnings [27] - AMG soared 9% on the heels of its Analyst Day [27]

[Applause] Sometimes when stocks are doing badly, I get worried. Not because I want to get out, but because I wonder if I might be missing a once in a generational bottom. Those don't come around all that often, of course.And right now I'm concerned that we might be missing a bottom in a group of stocks that I haven't particularly cared for at all, especially in a long time, including in How to Make Money in Any Market, which by the way, I'm signing tomorrow night, 6:30 p. m. Barnes & Noble on Atlantic in B ...

Market Performance & Outlook - The S&P 500 is up 36% from the April 8th lows and 16% year-to-date [2] - The economy is growing at 4% and productivity growth is running up 3% [2][3] - Earnings are growing 123%, revenues are growing 8%, both exceeding historical averages of 5% [4] - Fourth quarter growth is expected to be 8-12% cumulatively, suggesting a positive outlook [5] - The market has strong tailwinds, including accommodative global central banks and disinflationary trends [6] Technology Sector & AI - Technology is a key driver of the market, but investors are uncertain about the broadening out of the AI trade [8][12] - Mega-cap technology stocks experienced significant market cap fluctuations, adding $618 billion after losing $800 billion the previous week [10] - The market is differentiating between companies with explicable AI capex strategies and those with less clear paybacks [16] Investment Strategies & Considerations - Investors should consider whether they are overweight in technology and assess the potential for technology positions to be a source of liquidity in 2026 [9] - It's important to use stops and ride the best stocks in the market during the year-end meltup period [21] - There are opportunities beyond AI, with various stocks in uptrends and great technical setups, including commodities and energy stocks [19][20]

Market Overview - The S&P 500 and Nasdaq experienced declines due to pressure on Big Tech following CoreWeave's disappointing quarterly results, which included a lowered revenue outlook, leading to a 14% drop in CoreWeave's shares [1] - Wall Street is also reacting to soft labor market data, with ADP's payroll tracker indicating an average decline of 11,250 jobs over the four weeks ending October 25 [1] Company-Specific Updates - Linde's shares rose over 1% after UBS upgraded the company from a hold-equivalent rating to a buy, despite a price target reduction from $507 to $500, citing expected earnings-per-share growth in 2026 as a positive catalyst [1] - Nvidia's stock fell approximately 3% after SoftBank announced the sale of its entire stake in the company, which is part of a strategy to fund a $22.5 billion investment in OpenAI; this development does not raise concerns for Nvidia, maintaining the "own, don't trade" thesis [1] Additional Insights - The rapid-fire segment at the end of the video covered stocks including CoreWeave, Paramount Skydance, Amgen, Dutch Bros, and Coterra Energy [1] - Jim Cramer will be signing copies of his new book on market strategies, indicating ongoing engagement with investors [1]

Let's get right to the opening bell in the CNBC real time exchange at the big board. It's neuroscience alto neuroscience using AI to develop medications for neurological diseases at the NASDAQ as you saw before aboard the USS Intrepid, Senator Jerry Moran, chairman of uh Veterans Affairs, and Mona Dexter, VP of military and veteran affairs for Comcast, which has done a lot of good work with veterans over the years. >> Yeah, it's interesting.You're seeing a lot of companies trying to do neurological. Neurolo ...

Core Insights - The data presented indicates that lowering LDL cholesterol to a median target of 45 can reduce the risk of a first heart attack by 36% in the studied subjects [2][3] - The trial demonstrates that adding the drug Rapatha to optimized therapy can significantly prevent first occurrences of heart attacks and strokes, as well as potentially reduce cardiac death [2][3] Group 1: LDL Cholesterol and Heart Health - There is no level of cholesterol that is considered good, and the only way to achieve significant reduction is through medication [1] - The trial results confirm that lower LDL cholesterol levels are beneficial, with a targeted median of 45 showing meaningful benefits compared to a placebo group [3] Group 2: Drug Efficacy - The addition of Rapatha to existing therapies has shown a strong potential in preventing major heart-related issues, marking a significant advancement in treatment options [2][3]

Core Insights - The third-quarter 2025 reporting cycle for the Medical sector, which includes pharma/biotech and medical device companies, is nearing completion [1] Earnings Performance - Major pharmaceutical companies like Amgen, Novo Nordisk, and Pfizer reported earnings, with Amgen and Pfizer showing strong results and raising their EPS outlook for 2025, while Novo Nordisk faced weaker-than-expected results and reduced its full-year guidance due to slower growth in its GLP-1 portfolio [2] - As of November 5, nearly 82% of companies in the Medical sector, representing 92% of the sector's market capitalization, reported quarterly earnings, with approximately 92% beating earnings estimates and around 84% exceeding revenue expectations. Year-over-year earnings rose over 4%, while revenues increased nearly 11%, with overall expected increases of 3.0% in earnings and 10.5% in sales compared to the previous year [3] Potential Earnings Surprises - Four biotech companies—Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma, and Immuneering—are highlighted as likely to deliver earnings beats based on their positive Earnings ESP and solid Zacks ranks [4][10] - Alto Neuroscience has an Earnings ESP of +16.41% and a Zacks Rank 2, with a consensus estimate for a loss of 66 cents per share [7] - Autolus Therapeutics has an Earnings ESP of +22.30% and a Zacks Rank 2, with a consensus estimate for a loss of 23 cents per share [11] - Ascendis Pharma has an Earnings ESP of +34.28% and a Zacks Rank 3, with a consensus estimate for a loss of 41 cents per share [13] - Immuneering has an Earnings ESP of +21.62% and a Zacks Rank 3, with a consensus estimate for a loss of 37 cents per share [15]